EMCC European Monitoring Centre on Change



Geographic Location

Country: Ireland
Region: Dublin; Southern and Eastern
Location of affected unit(s): Dublin


Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Number Employed: 1000

Employment Effects

Announcement Date: 13-10-2022
Planned Job Reductions min: 400
Planned Job Reductions max: 400
Type of Restructuring: Internal restructuring
Employment Effect Start: 13-10-2022
Foreseen End Date: 31-10-2024
Direct Dismissals: 400

Additional Information

Novartis, a Swiss multinational pharmaceutical group has announced it will cut approximately 400 jobs at its Dublin office over the next two years. The company currently employs 1,000 people at its global service centre in Dublin and 500 people in Cork, however these jobs are unaffected.

The job cuts are part of a global restructuring to cut costs by $1 billion (€1.03bn). As part of this restructuring the company announced in early 2022, that it was to cut 8,000 jobs globally, or 7% of its 108,000-strong workforce.

Previous factsheets for Novartis have been recorded in the ERM database in 2022, with an announced global restructuring affecting 8000 employees globally (Novartis-2022-WO), and  the corresponding restructuring in Belgium (Novartis-2022-BE) and Spain (Novartis-2022-ES).